NEWARK, DE — Wilmington PharmaTech (WPT), a U.S.-based manufacturer of small molecule active pharmaceutical ingredients (API), announced that Los Angeles–based private equity firm Curewell Capital has made a majority investment in the company. The deal aims to accelerate WPT’s expansion and strengthen domestic pharmaceutical manufacturing capabilities.
Hui-Yin “Harry” Li, Ph.D., founder and CEO of Wilmington PharmaTech, will retain a significant ownership stake and continue leading the company alongside its existing management team. The partnership will provide substantial growth capital to expand WPT’s manufacturing footprint and enhance its end-to-end API development and production services.
Founded in 2003, WPT has become a trusted partner for global drug developers, offering integrated services spanning discovery, clinical development, and commercial-scale manufacturing. The company’s 54-acre Delaware campus houses two state-of-the-art facilities with cGMP and high potency API suites, complemented by an R&D center in Suzhou, China.
“Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies,” said Dr. Li. “We are committed to expanding our capabilities and capacity to better serve our global biopharmaceutical partners.”
Curewell Capital partner Michael Dal Bello praised WPT’s scientific depth and operational excellence, noting that the investment comes amid rising demand for specialized pharmaceutical manufacturing in the U.S. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity,” Dal Bello said.
The transaction positions Wilmington PharmaTech to capitalize on growing domestic and international demand for advanced API development, while expanding its role as a key U.S. manufacturing partner for biopharma innovators.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.